Eli Lilly Stays Ahead in Competitive Obesity Drug Market

Eli Lilly shares rose after trial data for retatrutide showed potential for industry-leading weight loss. While competitors like Roche and AstraZeneca presented new data at a major conference, analysts suggest Lilly remains the frontrunner in efficacy and market segmentation.